Compounders and drugmakers clash over compounded weight-loss drugs with FDA in the middle

A flurry of recent FDA announcements and legal maneuvers has placed two popular weight-loss drugs — tirzepatide (marketed as Mounjaro and Zepbound by Eli Lilly) and semaglutide (marketed as Ozempic and Wegovy by Novo Nordisk) — at the center of a growing squabble. Patients are desperate for affordable access, compounding pharmacies see a market opportunity, and brand manufacturers insist that compounding of their patented drugs infringes on their intellectual property and endangers public health. While the FDA itself has voiced concerns about compounded versions of FDA-approved GLP-1 therapies, the agency is allowing a grace period before taking enforcement action against state-licensed pharmacists/physicians compounding under section 503A (60 days) and outsourcing facilities under section 503B (90 days).

FDA resolves one shortage, may soon end another

In a declaratory order issued December 19, 2024, the FDA determined that tirzepatide products (Mounjaro and Zepbound) were no longer in short supply. This move, contested in Outsourcing Facilities Ass’n v. FDA, No. 4:24‐cv‐953 (N.D. Tex.), grants Eli Lilly a significant win in its effort to restrict compounding of its medications.

The FDA will not enforce FDCA provisions that typically prohibit compounding of “essentially a copy” of an approved drug until February 18, 2025, for 503A pharmacies and March 19, 2025, for 503B outsourcing facilities.

Meanwhile, semaglutide remains on the FDA’s shortage list for several dose strengths, though all doses have been reported as “available” since late October 2024.

Safety concerns, patent and affordability issues collide

The FDA has warned about potentially substandard quality, unlabeled salt forms, and dosing errors in compounded versions. Both Eli Lilly and Novo Nordisk assert that widespread compounding poses safety concerns and undermines their intellectual property rights. Lilly has requested to join ongoing litigation and sent cease-and-desist letters to telehealth companies and medical spas selling compounded tirzepatide.

Compounding pharmacies, especially larger 503B “outsourcing facilities,” maintain they provide an essential public service by offering lower-cost versions of medications that can cost over $1,000 per month. Many insurers still refuse to cover brand-name GLP-1 products for weight loss. Yet  the FDA has reported hundreds of adverse event reports allegedly linked to compounded versions of these drugs, which do not undergo the same rigorous manufacturing inspections and clinical testing as approved brands.

---

Filed Under: Metabolic disease/endicrinology
Tagged With: FDA enforcement grace period, GLP-1 drug shortages, Mounjaro supply chain, pharmaceutical compounding regulations, tirzepatide compounding
 

---